Literature DB >> 25255245

"En face" optical coherence tomography imaging in type 2 idiopathic macular telangiectasia.

Benjamin Wolff1, Chrysanthi Basdekidou, Vivien Vasseur, José-Alain Sahel, Alain Gaudric, Martine Mauget-Faÿsse.   

Abstract

PURPOSE: To comprehensively evaluate the retinal and choroidal changes in eyes with Type 2 idiopathic macular telangiectasia using "en face" and B-scan spectral domain optical coherence tomography (OCT), and to compare their respective contributions to this evaluation.
METHODS: Eyes with a diagnosis of proliferative or nonproliferative Type 2 macular telangiectasia were prospectively studied. All patients underwent an extensive ophthalmologic examination including biomicroscopic fundus examination, color photography, fundus autofluorescence, fluorescein angiography, B-scan and en face spectral domain OCT.
RESULTS: Twenty eyes of 10 patients were included in this study. En face OCT C-scans and conventional B-scans were both able to show inner crystalline deposits (15%), retinal capillary anomalies (100%), intraretinal cysts (80%), hyperreflective spots in the outer nuclear layer (100%) and external limiting membrane (80%), hyperplastic pigment plaques (30%), intraretinal neovascularization (20%), photoreceptor loss (100%), and choroidal cavitations (30%). En face OCT C-scans provided more information than B-scans on intraretinal neovascularization, photoreceptor loss, and choroidal cavitations. Also, en face OCT C-scans provided better visualization of the retinal vessels and telangiectasia than fluorescein angiography.
CONCLUSION: En face OCT is a noninvasive and reproducible technique that helps to better assess and follow up retinal and choroidal processes in Type 2 macular telangiectasia.

Entities:  

Mesh:

Year:  2014        PMID: 25255245     DOI: 10.1097/IAE.0000000000000208

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography.

Authors:  Marie-Louise Farecki; Matthias Gutfleisch; Henrik Faatz; Kai Rothaus; Britta Heimes; Georg Spital; Albrecht Lommatzsch; Daniel Pauleikhoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-23       Impact factor: 3.117

2.  Automated detection of photoreceptor disruption in mild diabetic retinopathy on volumetric optical coherence tomography.

Authors:  Zhuo Wang; Acner Camino; Miao Zhang; Jie Wang; Thomas S Hwang; David J Wilson; David Huang; Dengwang Li; Yali Jia
Journal:  Biomed Opt Express       Date:  2017-11-07       Impact factor: 3.732

3.  Subtle changes in diabetic retinas localised in 3D using OCT.

Authors:  Edmund Arthur; Joel A Papay; Bryan P Haggerty; Christopher A Clark; Ann E Elsner
Journal:  Ophthalmic Physiol Opt       Date:  2018-07-26       Impact factor: 3.117

4.  Correlation Between Macular Integrity Assessment and Optical Coherence Tomography Imaging of Ellipsoid Zone in Macular Telangiectasia Type 2.

Authors:  Dibyendu Mukherjee; Eleonora M Lad; Ryan R Vann; Stephanie J Jaffe; Traci E Clemons; Martin Friedlander; Emily Y Chew; Glenn J Jaffe; Sina Farsiu
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

5.  Idiopathic macular telangiectasia type 2: A six-year study with multimodal imaging of a presumed unilateral case.

Authors:  Mohammad Zarei; Mehdi Mazloumi; Reza Karkhaneh; Ramak Roohipoor
Journal:  J Curr Ophthalmol       Date:  2018-02-03

6.  OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study.

Authors:  Anne P Runkle; Peter K Kaiser; Sunil K Srivastava; Andrew P Schachat; Jamie L Reese; Justis P Ehlers
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-07-01       Impact factor: 4.799

7.  Visualization of Choriocapillaris and Choroidal Vasculature in Healthy Eyes With En Face Swept-Source Optical Coherence Tomography Versus Angiography.

Authors:  Jay C Wang; Inês Laíns; Rebecca F Silverman; Lucia Sobrin; Demetrios G Vavvas; Joan W Miller; John B Miller
Journal:  Transl Vis Sci Technol       Date:  2018-12-20       Impact factor: 3.283

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.